Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Aldeyra Therapeutics,Inc. (NASDAQ: ALDX).

Full DD Report for ALDX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALDX)

Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results - Earnings Call Transcript
Aldeyra Therapeutics, Inc. (ALDX) Q1 2018 Earnings Conference Call May 15, 2018 8:00 AM ET Executives Todd Brady - Chief Executive Officer of Aldeyra Therapeutics Steve Tulipano - Chief Financial Officer Analysts Neil Carnahan - Stifel John Newman - Canaccord Yale Jen - L...
Source: SeekingAlpha
Date: May, 15 2018 13:10
Aldeyra Therapeutics Announces First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 15, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced financial results for ...
Source: PR Newswire
Date: May, 15 2018 07:30
Aldeyra Therapeutics Appoints David McMullin as Senior Vice President, Corporate Development and Strategy
LEXINGTON, Mass. , May 10, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, announced the hiring of David McMullin to...
Source: PR Newswire
Date: May, 10 2018 08:00
Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
LEXINGTON, Mass. , May 9, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, will issue financial results for the quarter...
Source: PR Newswire
Date: May, 09 2018 08:00
Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at the Association for Research in Vision and Ophthalmology 2018 Annual Meeting
LEXINGTON, Mass. , May 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, presented the results of a randomized, doubl...
Source: PR Newswire
Date: May, 01 2018 07:00
2 Small Biotechs To Consider
If a man isn't willing to take some risk for his opinions, either his opinions are no good or he's no good ” ― Ezra Pound Today, we look at two developmental biotech concerns that seem to be offering attractive risk/reward profiles at current trading levels. Company Overv...
Source: SeekingAlpha
Date: April, 27 2018 10:50
Your Daily Pharma Scoop: Alder's Migraine Data, Centene Revenues, Tesaro's Positive Results
Analysis focus: Alder Biopharmaceuticals In mid-2017, despite seeing success in PROMISE 1, a phase 3 trial assessing Alder Biopharmaceuticals' (ALDR) eptinezumab targeting episodic migraine, the stock plummetted sharply. Investors were apparently not happy with the way the drug barely manage...
Source: SeekingAlpha
Date: April, 25 2018 08:00
Late-stage study underway for Aldeyra's allergic conjunctivitis med reproxalap; shares up 2%
The first patient has been enrolled in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' ( ALDX +2.1% ) reproxalap for the treatment of allergic conjunctivitis. More news on: Aldeyra Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 24 2018 10:06
Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 3 Clinical Trial
LEXINGTON, Mass. , April 24, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that it has enrolled the fir...
Source: PR Newswire
Date: April, 24 2018 08:00
Free Post Earnings Research Report: Curis' Quarterly Revenue Jumped 38.10%
Stock Monitor: Aldeyra Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on Curis, Inc. (NASDAQ: CRIS ). If you want access to this report all you need to do is sign up now by clicking the fo...
Source: ACCESSWIRE IA
Date: April, 19 2018 07:50

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-178.909.1759.2758.8674219,956
2017-06-204.504.254.504.2545,754
2017-06-194.454.454.554.3595,816
2017-06-164.104.304.454.1079,648
2017-06-154.604.154.654.00132,209

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-175,47411,11149.2665Short
2018-08-161,8107,70323.4973Cover
2018-08-152,00177,4682.5830Cover
2018-08-142,93472,4244.0511Cover
2018-08-133,64117,24221.1170Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALDX.


About Aldeyra Therapeutics,Inc. (NASDAQ: ALDX)

Logo for Aldeyra Therapeutics,Inc. (NASDAQ: ALDX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ALDX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 15 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 29 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: ALDX)

      Daily Technical Chart for (NASDAQ: ALDX)


      Stay tuned for daily updates and more on (NASDAQ: ALDX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ALDX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALDX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALDX and does not buy, sell, or trade any shares of ALDX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/